

A Novel Educational Program to Address Misunderstandings in Applying AASLD HBV Treatment Guidelines

Sarah L. Anderson, PharmD¹; Joseph Ahn, MD, MS, MBA^{2*}; Anna Christina L. dela Cruz, MD^{3*}; Paul Y. Kwo, MD^{4*}; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD^{4*}; Zachary Schwartz, MSc, ELS¹

1. Clinical Care Options. 2. Oregon Health & Science University. 3. University of Kentucky. 4. Stanford University.

*Potential conflicts of interest may exist. Refer to author disclosures section.

Background and Premise

- AASLD HBV management guidelines were updated in 2018 to include new recommendations
- A point-of-care app, *Hep B Consult*, was developed for HCPs seeking AASLD guidance
- In an analysis of 5698 cases entered into this app, HCPs’ management choice differed from AASLD recommendations in 40% of the cases

Aim

- To characterize the **educational impact** and **remaining knowledge gaps** among HCPs following tailored education on AASLD practice guidelines

Methods



- CCO released an **online educational program** on AASLD HBV treatment guidelines in February 2021
- Questions measuring **knowledge** and **competence** were asked at baseline and post education
- Key educational gaps** were identified using baseline and posteducation questions

Conclusion

- HCPs who care for patients with HBV have **significant knowledge gaps** in the areas of baseline assessment of fibrosis and the evaluation of fibrosis and inflammation
- 31% of learners reported that they planned to implement changes in their practice after participating in this targeted educational program


Supported by an educational grant from Gilead Sciences, Inc.
AASLD, American Association for the Study of Liver Diseases; HBV, hepatitis B virus; HCP, healthcare professional; HCC, hepatocellular carcinoma; NP, nurse practitioner; PA, physician associate/physician assistant.

Education Effective at Improving Knowledge and Competence Across a Range of HBV Care Issues, but Improvement in Specific Areas Needed



Learner Type and Practice Specialty

Figure. 3957 US learners participated in the educational program.



Author Disclosures

Joseph Ahn, MD: *consultant*: Gilead. Sarah L. Anderson, PharmD, has no relevant financial relationships to disclose. Anna Christina L. dela Cruz, MD: *researcher*: Novo Nordisk. Paul Y. Kwo, MD: *consultant/advisor/speaker*: Aligos, Antios, Assembly, Enanta, Gilead Sciences, Janssen; *researcher*: Bristol Myers Squibb, Eiger, Gilead Sciences, Janssen, Target Registries; *grant support*: Altimmune. Mindie H. Nguyen, MD: *consultant/advisor/speaker*: Eli Lilly, Exact Science, Gilead, GlaxoSmithKline, Intercept, Laboratory of Advanced Medicine; *researcher*: B.K. Kee Foundation, CurveBio, Enanta, Exact Sciences, Gilead, Glycotest, Helio Health, National Cancer Institute, Pfizer, Vir Biotech. Zachary Schwartz, MSc, has no relevant financial relationships to disclose.